Fenwick added a team of IP litigation partners—Jeffrey Oelke, Kevin McGann, James Trainor, Adam Gahtan, Robert Counihan and Ryan Johnson—to its New York office. The team is well-known for representing some of the world's preeminent life sciences, pharmaceutical, biotech and tech companies in high-profile patent litigation.
Oelke, McGann, and Fenwick managing partner Rodger Cole spoke with the New York Law Journal about this recent move.
“When we started talking with Fenwick, we were impressed by the fact they’re a full-service law firm focused on areas of tech and life sciences,” Oelke said. “That meshes very well with the clients we have and hope to serve.”
McGann said that they have heard favorable reactions from clients so far and that Fenwick is uniquely positioned to help companies navigate the significant legal issues that arise as the life sciences and technology industries converge, in areas like personalized medicine and digital health.
“The team is known as one of the most successful IP litigation groups in the country,” Cole said. He mentioned that adding these six highly accomplished partners—including multiple first-chair litigators—meets clients’ growing needs, and supports the firm’s strategy to leverage New York’s legal talent.
Fenwick’s New York office is rapidly growing, having more than quadrupled in size in less than two years. In addition to these six new partners, Fenwick also added corporate partner Matthew Cantor earlier this summer and technology transactions partner Vejay Lalla in late July.
To learn more about the firm’s new IP litigators, read the full New York Law Journal article. The story was also covered in BloombergLaw and Law360 (subscriptions required).
For more information, also see Fenwick’s announcement about the new additions.